Hasselmann Jonathan P C, Karim Hawra, Khalaj Anna J, Ghosh Subir, Tiwari-Woodruff Seema K
Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA 92521, USA.
Department of Statistics, UCR-CNAS, Riverside, CA 92521, USA.
J Neurosci Methods. 2017 Jun 1;284:71-84. doi: 10.1016/j.jneumeth.2017.04.003. Epub 2017 Apr 8.
While many groups use experimental autoimmune encephalomyelitis (EAE) as a model to uncover therapeutic targets and understand the pathology underlying multiple sclerosis (MS), EAE protocol variability introduces discrepancies in central nervous system (CNS) pathogenesis and clinical disease, limiting the comparability between studies and slowing much-needed translational research.
Here we describe a detailed, reliable protocol for chronic EAE induction in C57BL/6 mice utilizing two injections of myelin oligodendrocyte glycoprotein (35-55) peptide mixed with complete Freund's adjuvant and paired with pertussis toxin.
The active MOG-EAE protocol presented here induces ascending paralysis in 80-100% of immunized mice. We observe: (1) consistent T cell immune activation, (2) robust CNS infiltration by peripheral immune cells, and (3) perivascular demyelinating lesions concurrent with axon damage in the spinal cord and various brain regions, including the optic nerve, cortex, hippocampus, internal capsule, and cerebellum.
COMPARISON WITH EXISTING METHOD(S): Lack of detailed protocols, combined with variability between laboratories, make EAE results difficult to compare and hinder the use of this model for therapeutic development. We provide the most detailed active MOG-EAE protocol to date. With this protocol, we observe high disease incidence and a consistent, reliable disease course. The resulting pathology is MS-like and includes optic neuritis, perivascular mononuclear infiltration, CNS axon demyelination, and axon damage in both infiltrating lesions and otherwise normal-appearing white matter.
By providing a detailed active MOG-EAE protocol that yields consistent and robust pathology, we aim to foster comparability between pre-clinical studies and facilitate the discovery of MS therapeutics.
虽然许多研究团队将实验性自身免疫性脑脊髓炎(EAE)作为一种模型,以揭示治疗靶点并了解多发性硬化症(MS)的潜在病理机制,但EAE方案的变异性导致中枢神经系统(CNS)发病机制和临床疾病存在差异,限制了研究之间的可比性,并减缓了急需的转化研究。
在此,我们描述了一种详细、可靠的方案,用于在C57BL/6小鼠中诱导慢性EAE,该方案使用两次注射髓鞘少突胶质细胞糖蛋白(35-55)肽,并与完全弗氏佐剂混合,同时注射百日咳毒素。
本文介绍的活性MOG-EAE方案可使80-100%的免疫小鼠出现上行性麻痹。我们观察到:(1)持续的T细胞免疫激活;(2)外周免疫细胞对中枢神经系统的强力浸润;(3)脊髓和包括视神经、皮质、海马体、内囊和小脑在内的各个脑区出现血管周围脱髓鞘病变,并伴有轴突损伤。
缺乏详细的方案,再加上不同实验室之间的差异,使得EAE的结果难以比较,并阻碍了该模型在治疗开发中的应用。我们提供了迄今为止最详细的活性MOG-EAE方案。通过该方案,我们观察到高发病率和一致、可靠的病程。所产生的病理变化类似MS,包括视神经炎、血管周围单核细胞浸润、中枢神经系统轴突脱髓鞘以及浸润性病变和外观正常的白质中的轴突损伤。
通过提供一种能产生一致且严重病理变化的详细活性MOG-EAE方案,我们旨在促进临床前研究之间的可比性,并推动MS治疗方法的发现。